چهارشنبه 5 اردیبهشت 1403
[Archive]
دوره 8، شماره 3 - ( 4-1389 )
جلد 8 شماره 3 صفحات 134-131 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Suganthi R, Manonayaki S, Fathima Benazir J A. Follistatin concentrations in women from Kerala with polycystic ovary syndrome. IJRM 2010; 8 (3) :131-134
URL: http://ijrm.ir/article-1-185-fa.html
URL: http://ijrm.ir/article-1-185-fa.html
Follistatin concentrations in women from Kerala with polycystic ovary syndrome. International Journal of Reproductive BioMedicine. 1389; 8 (3) :131-134
چکیده: (2443 مشاهده)
Background: Polycystic ovary syndrome (PCOS) is a disorder in which there are numerous benign cysts that form on ovaries under a thick white covering that is one of the causes of infertility. Follistatin is a single chain glycosylated polypeptide that can bind to activin. When follistatin binds to activin it suppresses the role of activin to stimulate the secretion of Follicle Stimulating Hormone (FSH). FSH plays an important role in folliculogenesis and decrease in FSH level may arrest follicular development.
Objective: The aim is this study was to determine the circulating follistatin concentrations in PCOS patients compared to regularly menstruating women. Materials and Methods: The PCOS study group consisted of 88 oligo/amenorrheic women with PCOS. The control group consisted of 60 healthy women with regular menstrual cycles (26–30 days) and with no signs of hyperandrogenism. Body mass index (BMI Kg/m2) was calculated. Serum follistatin Serum Leutenizing hormone (LH) and FSH were determined. Student’s t-test and Pearson correlation coefficients were used carried out statistical analysis of the data.
Results: Serum follistatin levels were 0.11±0.04 and 0.31±0.08 ng/ml in control subjects and PCOS patients respectively (mean ± SD) and mean follistatin concentration in PCOS was high. The relationship between serum follistatin and FSH for control study was negatively correlated (r= -0.107 p=0.415) and was not significant whereas for PCOS patients the correlation was negative (r= -0.011 p=0.027) and however significant.
Conclusion: Follistatin concentrations were high in PCOS patients compared to control subjects in this study. The high concentration of follistatin in PCOS decreased the FSH level and thus follistatin and FSH levels were negatively correlated in this study.
Objective: The aim is this study was to determine the circulating follistatin concentrations in PCOS patients compared to regularly menstruating women. Materials and Methods: The PCOS study group consisted of 88 oligo/amenorrheic women with PCOS. The control group consisted of 60 healthy women with regular menstrual cycles (26–30 days) and with no signs of hyperandrogenism. Body mass index (BMI Kg/m2) was calculated. Serum follistatin Serum Leutenizing hormone (LH) and FSH were determined. Student’s t-test and Pearson correlation coefficients were used carried out statistical analysis of the data.
Results: Serum follistatin levels were 0.11±0.04 and 0.31±0.08 ng/ml in control subjects and PCOS patients respectively (mean ± SD) and mean follistatin concentration in PCOS was high. The relationship between serum follistatin and FSH for control study was negatively correlated (r= -0.107 p=0.415) and was not significant whereas for PCOS patients the correlation was negative (r= -0.011 p=0.027) and however significant.
Conclusion: Follistatin concentrations were high in PCOS patients compared to control subjects in this study. The high concentration of follistatin in PCOS decreased the FSH level and thus follistatin and FSH levels were negatively correlated in this study.
نوع مطالعه: Original Article |
فهرست منابع
1. Balen A, Michelmore K. What is polycystic ovary syndrome? Are national views important? Hum Reprod 2002; 17: 2219-2227. [DOI:10.1093/humrep/17.9.2219]
2. Stein IF, Leventhal ML. Amenorrhoea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29: 181-191. [DOI:10.1016/S0002-9378(15)30642-6]
3. Gabor T Kovacs. Polycystic ovary syndrome, Cambridge University Press 2000; 1 - 4
4. Elsenbruch S, Hahn S, Kowalsky D, Offner AH, Schedlowski M, Mann K, Janssen OE. Quality of life, psychosocial wellbeing, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 5801-5807. [DOI:10.1210/jc.2003-030562]
5. Hardiman P, Pillay OS, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003; 361: 1810-1812. [DOI:10.1016/S0140-6736(03)13409-5]
6. Vural B. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum Reprod 2005; 20: 2409-2413. [DOI:10.1093/humrep/dei100]
7. Rivier C and Vale W. Effect of recombinant activin- A on gonadotropin secretion in the female rat. Endocrinology 1991; 129: 2463-2465. [DOI:10.1210/endo-129-5-2463]
8. Ogawa T, Hirose H, Yamamoto Y, Nishikai K, Miyashita K, Nakamura H, Saito I, Saruta T. Relationships between serum soluble leptin receptor level and serum leptin and adiponectin levels, insulin resistance index, lipid profile, and leptin receptor gene polymorphisms in the Japanese population. Metabolism 2004; 53: 879-885. [DOI:10.1016/j.metabol.2004.02.009]
9. de Kretser DM, Foulds LM, Hancock M. Partial characterization of inhibin, activin, and follistatin in the term human placenta. J Clin Endocrinol Metab 1994; 79: 502-507.
10. Petraglia F, Gallinelli A, De Vita D. Activin and parturition: changes of maternal serum levels and evidence for binding sites in placenta and fetal membranes. Obstet Gynecol 1994; 84: 278-282.
11. Norman RJ, Milner CR, Groome NP, Robertson DM. Circulating follistatin concentrations are higher and activin concentrations are lower in polycystic ovarian syndrome. Hum reprod 2001; 16: 668-672. [DOI:10.1093/humrep/16.4.668]
12. Xiao S, Robertson DM, Findlay JK. Effects of activin and follicle-stimulating hormone (FSH)-suppressing protein/follistatin on FSH receptors and differentiation of cultured rat granulosa cells. Endocrinology 1992; 131: 1009-1016. [DOI:10.1210/endo.131.3.1505447]
13. Guo Q, Kumar TR, Woodruff T, Hadsell LA, DeMayo FJ, Matzuk MM. Over expression of mouse follistatin causes reproductive defects in transgenic mice. Mol Endocrinol 1998; 12: 96-106. [DOI:10.1210/mend.12.1.0053]
14. Zawadzki JK, Dunaif A. Diagnostic criteria for Polycystic Ovary Syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic ovary syndrome. Boston: Blackwell Scientific 1992; 377-384.
15. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop groups, consensus on diagnostic criteria and long-term health risks related Polycystic Ovary Syndrome. Fertil Steril 2004; 81: 19-25.
16. Bianco AT, Smilen SW, Davis Y. Pregnancy outcome and weight gain recommendations for the morbidly obese woman. Obstet Gynecol 1998; 91: 97-102. [DOI:10.1016/S0029-7844(97)00578-4]
17. Rajkowha M, Glass MR, Rutherford AJ, Michelmore K, Balen AH. Polycystic Ovary Syndrome: a risk factor for cardiovascular disease? Br J Obs Gynaecol 2000; 107: 11-18. [DOI:10.1111/j.1471-0528.2000.tb11572.x]
18. Balen AH. Polycystic ovary syndrome and cancer. Hum Reprod Update 2001; 7: 522-525. [DOI:10.1093/humupd/7.6.522]
19. Wang JX, Davies MJ, Norman RJ. Obesity increases the risk of spontaneous abortion during infertility treatment. Obes Res 2002; 10: 551-554. [DOI:10.1038/oby.2002.74]
20. Urbanek M, Legro RS, Driscoll DA. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci USA 1999; 96: 8573-8578. [DOI:10.1073/pnas.96.15.8573]
21. Magoffin DA, Jakimiuk AJ. Inhibin A, inhibin B and activin A concentrations in follicular fluid from women with polycystic ovary syndrome. Hum Reprod 1998; 13: 2693-2698. [DOI:10.1093/humrep/13.10.2693]
22. Liao WX, Roy AC, Ng SC. Preliminary investigation of follistatin gene mutations in women with polycystic ovary syndrome. Mol Hum Reprod 2000; 6: 587-590. [DOI:10.1093/molehr/6.7.587]
23. Eldar-Geva T, Spitz IM, Groome NP, Margalioth EJ, Homburg R. Follistatin and activin A serum concentrations in obese and non-obese patients with polycystic ovary syndrome. Hum Reprod 2001; 16: 2552-2556. [DOI:10.1093/humrep/16.12.2552]
24. Phillips KP, Leveille MC, Claman P. Changes in serum inhibin, activin and follistatin concentrations during puberty in girls. Hum Reprod 2000; 15: 1052-1057. [DOI:10.1093/humrep/15.5.1052]
25. Odunsi K, Kidd KK. A Paradigm for Finding Genes for a Complex Human Trait: Polycystic Ovary Syndrome and Follistatin. Proc of the Natl Acad Sci USA 1999; 96: 8315-8317. [DOI:10.1073/pnas.96.15.8315]
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
